[Changes of genomic density polymorphism and quantitative expression of complement receptor type 1 in patients with liver diseases].
OBJECTIVE
To study the changes of genomic density polymorphism and quantitative expression of complement receptor type 1 (CR1) on erythrocytes in patients with liver diseases.


METHODS
Polymerase chain reaction (PCR) and Hind III restriction enzyme digestion and the quantitative assay of erythrocytic CR1 were used.


RESULTS
The spot mutation rate (25.0% approximately 30.3%) of erythrocyte CR1 density gene in patients with liver diseases was not significantly different with that of healthy individuals (28.0%). The amount of erythrocytic CR1 in patients with liver diseases, except for those with normal liver function, was significantly lower than that of healthy individuals (t=10.44, P<0.0001). The quantitative expression of erythrocytic CR1 in decompensated cirrhosis was obviously lower than that of compensated cirrhosis (t=2.21, P<0.05).


CONCLUSIONS
Defective expression of CR1 in liver diseases is acquired through central and/or peripheral mechanisms. It is very important to study the quantitative expression in the evaluation of the development of liver diseases.
Wang
H
H
Department of Immunology, Changhai Hospital, The Second Military Medical University, Shanghai 200433, China.
Qian
B
B
Niu
F
F
Jiang
A
A
D004912:Erythrocytes / Q000737:chemistry*; D005838:Genotype; D006801:Humans; D008099:Liver / Q000503:physiopathology; D008107:Liver Diseases / Q000235:genetics / Q000276:immunology* / Q000503:physiopathology; D011110:Polymorphism, Genetic; D017463:Receptors, Complement 3b / Q000032:analysis / Q000235:genetics*
D017463:Receptors, Complement 3b